Identity
One molecule, three receptor systems.
LUV RT is an investigational compound designed to activate receptors for receptor pathway B, receptor pathway A, and receptor pathway C. Research interpretation requires attention to relative receptor activity, exposure, participant characteristics, and the endpoint being measured.
A short informal code is not a substitute for a defined chemical identity in scientific documentation.
Evidence map
Selected published research.
Phase 2 imaging-based composition study
Randomized trialA 2023 publication described a 48-week placebo-controlled study in 338 adults. The protocol used several randomized groups and prospectively defined protocol-defined endpoints.
Limit: a Phase 2 result is not a universal conclusion; duration, attrition, group assignment, and sponsor involvement are part of the evidence record.
Phase 2 metabolic-marker study
Randomized trialA separate 2023 publication evaluated metabolic-marker endpoints in adults with a defined metabolic study population using placebo and active comparators.
Limit: findings from this population and protocol should not be transferred to other research questions.
TRIUMPH-1
Registered protocolPublic protocol registry lists a randomized, double-blind, placebo-controlled master protocol under identifier NCT05929066.
Limit: a registry record describes a study plan and status; it is not itself a peer-reviewed result.
Design lessons
Read beyond the headline endpoint.
- Confirm whether an analysis was prespecified and how missing observations were handled.
- Review absolute values, uncertainty intervals, and comparator results alongside percentages.
- Separate biomarker, imaging-based composition, metabolic-marker, and safety endpoints.
- Distinguish published results from registered but not yet reported protocols.
Interpretive limits
Investigational evidence changes over time.
Later studies may refine or contradict earlier estimates. A responsible summary identifies the publication date and study phase, avoids extending group averages to individuals, and does not treat an ongoing development program as a settled evidence base.
Selected primary sources
Source notes.
- Triple-Hormone-Receptor Agonist LUV RT for composition endpoints — A Phase 2 Trial. New England Journal of Medicine. 2023. DOI 10.1056/NEJMoa2301972.
- LUV RT, a pathway B, pathway A and receptor pathway C agonist, for people with a defined metabolic study population: a phase 2 trial. Lancet. 2023. PMID 37385280.
- A Study of LUV RT (catalogued study compound) in Participants Who Have composition endpoints or composition criteria. Public protocol registry identifier NCT05929066.